# Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular Correlates

> **NCT00104728** · NA · TERMINATED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 42 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** ZD1839

## Key facts

- **NCT ID:** NCT00104728
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-10
- **Primary completion:** 2008-05
- **Final completion:** 2009-03
- **Target enrollment:** 42 (ACTUAL)
- **Why stopped:** Early Stopping Rule: Would not meet interim analysis goal to proceed with enrollment
- **Last updated:** 2012-10-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00104728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00104728, "Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular Correlates". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00104728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*